+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group



Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group



Journal of Clinical Oncology 22(2): 254-261



Few randomized trials have demonstrated survival benefit of combination chemotherapy involving new agents plus cisplatin compared with classic combination chemotherapy in advanced non-small-cell lung cancer (NSCLC). The primary aim of this study was to test whether docetaxel plus cisplatin (DC) improves survival compared with vindesine plus cisplatin (VdsC) in patients with previously untreated stage IV NSCLC. Eligible, stage IV, chemotherapy-naive patients (n = 311) were randomly assigned to receive docetaxel 60 mg/m(2) intravenously on day 1 plus cisplatin 80 mg/m(2) intravenously on day 1 of a 3- or 4-week cycle, or vindesine 3 mg/m(2) intravenously on days 1, 8, and 15 plus cisplatin 80 mg/m(2) intravenously on day 1 of a 4-week cycle. Cross-over administration of docetaxel and vindesine was prohibited for both treatment groups. Overall, 302 patients were eligible for evaluation. The DC arm demonstrated significant improvements compared with the VdsC arm in overall response rates (37% v 21%, respectively; P <.01) and median survival times (11.3 v 9.6 months, respectively; P =.014). Two-year survival rates were 24% for the DC arm compared with 12% for the VdsC arm. The physical domain of the Quality of Life for Cancer Patients Treated with Anticancer Drugs measure was significantly better in the DC arm than in the VdsC arm (P =.020). Toxicity was predominantly hematologic and was more severe in the VdsC arm. As first-line treatment for stage IV NSCLC, DC resulted in greater clinical benefit in terms of response rate (with marked improvements in overall and 2-year survival rates) and quality of life than did treatment with VdsC.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 049909797

Download citation: RISBibTeXText

PMID: 14722033

DOI: 10.1200/jco.2004.06.114


Related references

A randomized phase III trial of docetaxel and cisplatin versus vindesine and p in stage IV non small cell lung cancer. European Journal of Cancer 37(Suppl. 6): S48, 2001

A phase III randomized trial of cisplatin plus vindesine versus cisplatin plus vindesine plus mitomycin C versus cisplatin plus vindesine plus ifosfamide for advanced non-small-cell lung cancer. Respirology 1(1): 49-54, 1996

A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial. Annals of Oncology 26(7): 1401-1408, 2016

A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin. Journal of Clinical Oncology 9(4): 606-613, 1991

Randomized, multi-center phase II trial of docetaxel plus cisplatin versus etoposide plus cisplatin as the first-line therapy for patients with advanced non-small cell lung cancer. Cancer Research and Treatment 37(6): 332-338, 2005

Randomized Phase III Trial of Oral S-1 Plus Cisplatin Versus Docetaxel Plus Cisplatin for Advanced Non-small-cell Lung Cancer. Nihon Naika Gakkai Zasshi 102(5): 1248-1251, 2013

Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. Journal of Clinical Oncology 21(17): 3207-3213, 2003

Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer. Clinical Lung Cancer 7(5): 353-356, 2006

Randomized phase III trial of docetaxel and cisplatin combination chemotherapy versus mitomycin, vindesine and cisplatin combination chemotherapy with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer: Preliminary report. Journal of Clinical Oncology 24(18_Suppl): 7101-7101, 2016

Randomized phase III trial of docetaxel and cisplatin combination chemotherapy versus mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer: OLCSG 0007. Journal of Clinical Oncology 26(15_Suppl): 7515-7515, 2016

A prospective randomized trial comparing mitomycin C and vindesine and cisplatin versus pirarubicin and vindesine and cisplatin in the treatment of advanced non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 6(3): 195-197, 2003

A randomized phase III trial of adjuvant chemotherapy with cisplatin and vindesine followed by UFT for completely resected pathologic (p-) stage IIIA-N2 non-small cell lung cancer (NSCLC): West Japan Study Group for Lung Cancer Surgery (WJSG) - the 5 th Study. Journal of Clinical Oncology 23(16_Suppl): 7262-7262, 2016

A randomized trial comparing vindesine plus cisplatin with mitomycin C, vindesine plus cisplatin in patients with advanced non-small cell lung cancer. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 14(9): 2676-2681, 1987

Randomized Phase III Study of Docetaxel Plus Cisplatin Versus Pemetrexed Plus Cisplatin as First-line Treatment of Nonsquamous Non-Small-cell Lung Cancer: A TRAIL Trial. Clinical Lung Cancer 18(4): E289-E296, 2017

Randomized trial of cisplatin plus ifosfamide versus cisplatin plus vindesine for non-small cell lung cancer (NSCLC). Gan to Kagaku Ryoho. Cancer and ChemoTherapy 19(1): 61-67, 1992